Pancho, thanks for your posts.
When you get a chance, you ought to read the four studies published last year; and get your hands on the six abstracts of the studies presented at AADR last week for peer review.
I'm aware of Enamelon's financial position. It does not have $100 million to burn on a nationwide blitz, like Total, which started in January and continues today.
Rather, as Dr. Fox indicated in recent release, Enamelon is going to take a phase approach to rollout. For example, it's already comlete in the State of Florida. So the revenues from that activity will be used to fund the next phase, and so on.
But, I agree. If not careful with expenses, ENML could get into trouble. However, they appear to have been very modest so far, as one poster indicated at a recent Chicago dental meeting.
Obviously, ENML is going to rely on media to help market its product, once the studies results are finally made public.
Greg |
